MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma
Open Access
- 21 February 2022
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2035919
Abstract
The major histocompatibility complex-class I chain related proteins A and B (MICA/B) is upregulated because of cellular stress and MICA/B shedding by cancer cells causes escape from NKG2D recognition favoring the emergence of cancers. Cholangiocarcinoma (CCA) is a relatively rare, though increasingly prevalent, primary liver cancer characterized by a late clinical presentation and a dismal prognosis. We explored the NKG2D-MICA/B axis in NK cells from 41 patients with intrahepatic cholangiocarcinoma (iCCA). The MICA/B-specific 7C6 mAb was used for ex vivo antibody-dependent cytotoxicity (ADCC) experiments using circulating, non tumor liver- and tumor-infiltrating NK cells against the HuCCT-1 cell line and patient-derived primary iCCA cells as targets. MICA/B were more expressed in iCCA than in non-tumoral tissue, MICA transcription being higher in moderately-differentiated compared with poorly-differentiated cancer. Serum MICA was elevated in iCCA patients in line with higher expression of ADAM10 and ADAM17 that are responsible for proteolytic release of MICA/B from tumor. Addition of 7C6 significantly boosted peripheral, liver- and tumor-infiltrating-NK cell degranulation and IFNγ production toward MICA/B-expressing established cell lines and autologous iCCA patient target cells. Our data show that anti-MICA/B drives NK cell anti-tumor activity, and provide preclinical evidence in support of 7C6 as a potential immunotherapeutic tool for iCCA.Keywords
Funding Information
- Ministero della Salute (08071219)
- Ministry of Health, Ricerca Corrente (08071219)
This publication has 58 references indexed in Scilit:
- Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular CarcinomaPLOS ONE, 2012
- NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational studyBMC Cancer, 2012
- Secretome-Based Identification of ULBP2 as a Novel Serum Marker for Pancreatic Cancer DetectionPLOS ONE, 2011
- ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patientsInternational Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and MetalloproteinasesThe Journal of Immunology, 2010
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for ImmunoeditingClinical Cancer Research, 2009
- Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100BClinical Cancer Research, 2009
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- Expression of Stress-induced MHC Class I Related Chain Molecules on Human MelanomaJournal of Investigative Dermatology, 2002